Agnieszka Wegner1, Aleksandra Banaszkiewicz2, Jaroslaw Kierkus3, Piotr Landowski4, Anna Korlatowicz-Bilar5, Sabina Wiecek6, Jaroslaw Kwiecien7, Agnieszka Gawronska2, Lukasz Dembinski2, Grazyna Czaja-Bulsa8, Piotr Socha3. 1. Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland; Department of Gastroenterology, Hepatology, Nutritional Disorders and Paediatrics, Children's Memorial Health Institute, Warsaw, Poland. Electronic address: wegner.agnieszka@gmail.com. 2. Department of Paediatrics, Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland. 3. Department of Gastroenterology, Hepatology, Nutritional Disorders and Paediatrics, Children's Memorial Health Institute, Warsaw, Poland. 4. Department of Paediatrics, Gastroenterology and Eating Disorders, Medical University of Gdansk, Gdansk, Poland. 5. Department of Paediatrics, Gastroenterology and Rheumatology, Children's Hospital, Szczecin, Poland. 6. Department of Paediatrics, Gastroenterology Unit, Medical University of Silesia, Katowice, Poland. 7. Department of Gastroenterology, Hepatology of Children, Medical University of Silesia, Zabrze, Poland. 8. Department of Paediatrics, Gastroenterology and Rheumatology, Children's Hospital, Szczecin, Poland; Paediatrics and Paediatric Nursery Unit, Pomeranian Medical University, Szczecin, Poland.
Abstract
OBJECTIVE:Constipation is one of the most common problems among children, with a prevalence ranging from 7 to 30%. It is treated with defecation training and laxative medications. However, many patients do not respond to the standard therapy. There is, therefore, an increasing interest in probiotics for the treatment of functional constipation. STUDY DESIGN: The aim of this study was to assess the effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional, intractable constipation in children. A double-blind, placebo-controlled, randomized, multicentre trial involved a group of 129 children with functional constipation who were treated with a poor effect for at least two months prior to the study. Patients were randomly assigned to one of the two groups: 1. L. reuteri DSM 17938 and macrogol or 2. macrogol and matching placebo for 8 weeks. RESULTS:121 patients completed the study. Almost all patients (119/129) increased their bowel movements in both groups (59 vs 60, ns.) and there was no statistically significant difference in the number of bowel movements per week in week 8 between the study and the placebo group (7.5±3.3 vs 6.9±2.5, respectively). Additionally, there were no significant differences between groups in the numbers of patients complaining of pain during defecation (13/47 vs 8/53), abdominal pain (19/41 vs 25/36), withholding stools (15/45 vs 13/48), passing hard stools (7/53 vs 3/58) or large stools (14/46 vs 12/49), and faecal incontinence (17/43 vs 11/50). CONCLUSION: L. reuteri DSM 17938 supplementation as an additional therapy to macrogol did not have any beneficial effect on the treatment of functional constipation in children aged 3-7 years.
RCT Entities:
OBJECTIVE:Constipation is one of the most common problems among children, with a prevalence ranging from 7 to 30%. It is treated with defecation training and laxative medications. However, many patients do not respond to the standard therapy. There is, therefore, an increasing interest in probiotics for the treatment of functional constipation. STUDY DESIGN: The aim of this study was to assess the effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional, intractable constipation in children. A double-blind, placebo-controlled, randomized, multicentre trial involved a group of 129 children with functional constipation who were treated with a poor effect for at least two months prior to the study. Patients were randomly assigned to one of the two groups: 1. L. reuteri DSM 17938 and macrogol or 2. macrogol and matching placebo for 8 weeks. RESULTS: 121 patients completed the study. Almost all patients (119/129) increased their bowel movements in both groups (59 vs 60, ns.) and there was no statistically significant difference in the number of bowel movements per week in week 8 between the study and the placebo group (7.5±3.3 vs 6.9±2.5, respectively). Additionally, there were no significant differences between groups in the numbers of patients complaining of pain during defecation (13/47 vs 8/53), abdominal pain (19/41 vs 25/36), withholding stools (15/45 vs 13/48), passing hard stools (7/53 vs 3/58) or large stools (14/46 vs 12/49), and faecal incontinence (17/43 vs 11/50). CONCLUSION:L. reuteri DSM 17938 supplementation as an additional therapy to macrogol did not have any beneficial effect on the treatment of functional constipation in children aged 3-7 years.
Authors: David Avelar Rodriguez; Jelena Popov; Elyanne M Ratcliffe; Erick Manuel Toro Monjaraz Journal: Front Pediatr Date: 2021-01-20 Impact factor: 3.418
Authors: Andrea A García Contreras; Edgar M Vásquez Garibay; Carmen A Sánchez Ramírez; Mary Fafutis Morris; Vidal Delgado Rizo Journal: Nutrients Date: 2020-09-28 Impact factor: 5.717